MX2021006982A - Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. - Google Patents
Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.Info
- Publication number
- MX2021006982A MX2021006982A MX2021006982A MX2021006982A MX2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A
- Authority
- MX
- Mexico
- Prior art keywords
- organophosphorus
- met inhibitors
- therapeutic uses
- substituted compounds
- triazolo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical class C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- SVHARYIFQFSECW-UHFFFAOYSA-N [1,2,4]triazolo[4,3-b][1,2,4]triazine Chemical compound N1=CC=NN2C=NN=C21 SVHARYIFQFSECW-UHFFFAOYSA-N 0.000 abstract 1
- YRACHDVMKITFAZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1=CC=NN2C=NN=C21 YRACHDVMKITFAZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5004—Acyclic saturated phosphines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación provee derivados de [1,2,4]triazolo[4,3-b] [1,2,4]triazina, [1,2,4]triazolo[4,3-b]piridazina y [1,2,3]triazolo[4,5-b]pirazina, y sales, solvatos o profármacos farmacéuticamente aceptables de los mismos, como inhibidores de la tirosina cinasa c-MET, los cuales son útiles como agentes anticancerosos y/o antiinflamatorios novedosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779960P | 2018-12-14 | 2018-12-14 | |
PCT/US2019/066414 WO2020124060A1 (en) | 2018-12-14 | 2019-12-14 | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006982A true MX2021006982A (es) | 2021-09-10 |
Family
ID=71077551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006982A MX2021006982A (es) | 2018-12-14 | 2019-12-14 | Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220064194A1 (es) |
EP (1) | EP3893872B1 (es) |
JP (1) | JP2022513215A (es) |
KR (1) | KR20210111779A (es) |
CN (1) | CN113412112B (es) |
AU (1) | AU2019395282A1 (es) |
BR (1) | BR112021011547A2 (es) |
CA (1) | CA3122575A1 (es) |
EA (1) | EA202191541A1 (es) |
IL (1) | IL283589A (es) |
MX (1) | MX2021006982A (es) |
SG (1) | SG11202105872RA (es) |
TW (1) | TW202039500A (es) |
WO (1) | WO2020124060A1 (es) |
ZA (1) | ZA202104000B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116969955B (zh) * | 2023-09-25 | 2023-12-19 | 中国药科大学 | 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0620292B1 (pt) | 2005-12-21 | 2021-08-24 | Janssen Pharmaceutica N. V. | Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto |
NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
US20110039856A1 (en) * | 2007-11-29 | 2011-02-17 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
EA025466B1 (ru) | 2009-12-31 | 2016-12-30 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术(太仓)有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
JP6659850B2 (ja) * | 2015-12-31 | 2020-03-04 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途 |
-
2019
- 2019-12-14 JP JP2021533641A patent/JP2022513215A/ja active Pending
- 2019-12-14 BR BR112021011547-1A patent/BR112021011547A2/pt not_active IP Right Cessation
- 2019-12-14 KR KR1020217022048A patent/KR20210111779A/ko unknown
- 2019-12-14 CA CA3122575A patent/CA3122575A1/en not_active Abandoned
- 2019-12-14 WO PCT/US2019/066414 patent/WO2020124060A1/en active Application Filing
- 2019-12-14 US US17/312,669 patent/US20220064194A1/en active Pending
- 2019-12-14 SG SG11202105872RA patent/SG11202105872RA/en unknown
- 2019-12-14 CN CN201980091722.3A patent/CN113412112B/zh active Active
- 2019-12-14 AU AU2019395282A patent/AU2019395282A1/en not_active Abandoned
- 2019-12-14 MX MX2021006982A patent/MX2021006982A/es unknown
- 2019-12-14 EA EA202191541A patent/EA202191541A1/ru unknown
- 2019-12-14 EP EP19897455.2A patent/EP3893872B1/en active Active
- 2019-12-16 TW TW108146055A patent/TW202039500A/zh unknown
-
2021
- 2021-05-31 IL IL283589A patent/IL283589A/en unknown
- 2021-06-10 ZA ZA2021/04000A patent/ZA202104000B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020124060A1 (en) | 2020-06-18 |
EP3893872A1 (en) | 2021-10-20 |
CN113412112B (zh) | 2024-06-11 |
CA3122575A1 (en) | 2020-06-18 |
JP2022513215A (ja) | 2022-02-07 |
CN113412112A (zh) | 2021-09-17 |
AU2019395282A1 (en) | 2021-07-08 |
ZA202104000B (en) | 2022-08-31 |
IL283589A (en) | 2021-07-29 |
EP3893872A4 (en) | 2022-08-10 |
EA202191541A1 (ru) | 2022-01-21 |
US20220064194A1 (en) | 2022-03-03 |
BR112021011547A2 (pt) | 2021-08-31 |
TW202039500A (zh) | 2020-11-01 |
SG11202105872RA (en) | 2021-07-29 |
KR20210111779A (ko) | 2021-09-13 |
EP3893872B1 (en) | 2024-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500775A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
PH12019501670A1 (en) | Kras g12c inhibitors and methods of using the same | |
WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
MX2018002916A (es) | Metodos, composiciones y usos de nuevos inhibidores de fyn quinasa. | |
NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
MX2020009586A (es) | Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk. | |
MX2018013133A (es) | Compuesto de pirazolo[1,5-a]pirimidina. | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2015012896A (es) | Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
PH12019500478A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof | |
NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
MX2021006982A (es) | Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. | |
IL280122A (en) | Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors | |
MX2020010084A (es) | Composiciones farmaceuticas anticancerigenas para terapia combinada. | |
EA201990940A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
EA201990939A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |